Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

Key Terms

automated insulin delivery medical

A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.

continuous glucose monitor medical

A continuous glucose monitor is a small device worn on the body that constantly tracks blood sugar levels throughout the day and night. It provides real-time data, helping individuals manage conditions like diabetes more effectively. For investors, advancements in this technology can signal growth opportunities in healthcare and medical device markets, reflecting broader trends in health technology innovation.

multiple daily injections medical

Multiple daily injections (MDI) is a diabetes treatment approach where a person takes several separate insulin shots each day—typically a long-acting dose to cover baseline needs and additional short-acting doses around meals. For investors, MDI signals demand for insulin supplies, injection devices and support services, and can affect adherence and health outcomes; think of it like needing both a monthly subscription and frequent one-off purchases, which shapes recurring revenue and product design opportunities.

subcutaneous medical

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

• The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors

• Inaugural launch of Omnipod Discover data management platform aims to lessen the burdens on healthcare providers and users, streamlining diabetes information into meaningful insights

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE). The Company is making the announcement at the 16^th edition of the Emirates Diabetes and Endocrine Congress (EDEC) in Dubai.

“We’re proud to bring Omnipod 5 to a region where the unmet need is great¹. These launches build on our significant momentum as we continue to transform the lives of people with diabetes worldwide,” said Pat Crannell, Insulet Senior Vice President and International General Manager. “It is even more meaningful and impactful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps us create a world where diabetes demands less, every day.”

The Omnipod 5 System simplifies diabetes management and has demonstrated strong glycemic outcomes, including improved time in range and lowering HbA1c, by automatically adjusting insulin delivery every five minutes and eliminating the need for multiple daily injections (MDI) ².

The waterproof³, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a sensor and proactively corrects for highs and helps to protect against lows, day and night^4,5.

Omnipod 5 is indicated for individuals aged two years and older with type 1 diabetes and compatible with the Abbott FreeStyle Libre 2 Plus sensor and the Dexcom G7 sensor in Saudi Arabia, Kuwait, and the UAE, and with the Dexcom G7 sensor in Qatar.

Omnipod Discover: Diabetes Data Management – Simplified

Insulet is also launching Omnipod Discover, a proprietary and retrospective data analytics and reporting platform designed for Omnipod 5 users, their caregivers, and healthcare providers. Easy to access, Omnipod Discover streamlines the analysis of glucose and insulin delivery data and delivers meaningful insights — transforming complex information into clear, relevant trends and recommendations that inform diabetes management. Its web-based intuitive display shows how the Omnipod 5 algorithm automates insulin delivery, enabling understanding of trends to make decisions confidently. Users can also access their data with insights in a simplified way that empowers them to understand and manage their diabetes.

Omnipod Discover is being introduced in these Middle Eastern markets first, with plans to expand to other countries where Omnipod 5 is available.

With these new market launches, Omnipod 5 is now available globally in 19 countries with plans to launch in Spain (a new market for Insulet) in 2026, followed by Greece and Croatia in the first half of 2027.

“People living with type 1 diabetes in Saudi Arabia and throughout the Middle East are eager for an innovative solution that is Omnipod 5. As our diabetes care standards in the region evolve to embrace advanced technologies that improve outcomes, the introduction of Omnipod 5 represents an important step forward that will transform daily life for many individuals and their families,” said Dr. Mohammed Almehthel, Medical Director and Diabetes Technology Section Head at the Obesity, Endocrinology and Metabolism Center (OEMC) at King Fahad Medical City (KFMC) in Saudi Arabia.

Khalid Al Shethri, who lives in Riyadh, Saudi Arabia, shared his excitement about his nine-year-old daughter Yasmeen who started on Omnipod 5. “We’re so happy Yasmeen is beginning her Omnipod 5 journey. She’s a lively, brilliant girl, and diabetes has been something she’s had to think about every single day. Now that school is such a big part of her life, it feels like a bit of her childhood is being given back, helping her feel freer and more confident.”

¹ International Diabetes Federation (IDF) Atlas 2025, 11^th Edition

² Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM.

³ The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof.

⁴ Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

⁵ Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary materially from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205745251/en/

Investor Relations:

Clare Trachtman

Vice President, Investor Relations

ir@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

pr@insulet.com

Source: Insulet Corporation